Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

Detailed summary
Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab. The post Summit Crumbles After FDA…
Summit Therapeutics (SMMT) stock crashed Monday after the Food and Drug Administration rejected its Merck (MRK)-rivaling lung cancer drug, ivonescimab. Leerink Partners analyst Daina Graybosch wasn't surprised, noting the FDA said ivonescimab in combination with chemotherapy would need to improve overall survival to win approval. Overall survival is how long patients live before dying of any cause. The regimen failed…
Opening of the article, excerpted from Investor's Business Daily. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)